100683-08-7

Basic information

• Product Name: 1-METHOXYCYCLOPROPANE-1-CARBOXYLIC ACID
• Synonyms: 1-METHOXYCYCLOPROPANE-1-CARBOXYLIC ACID;Cyclopropanecarboxylic acid, 1-methoxy-
• CAS NO: 100683-08-7
• Molecular Formula: C₅H₈O₃
• Molecular Weight: 116.11522
• EINECS: -0
• Mol File: 100683-08-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 203.3±23.0 °C(Predicted)
• Appearance: /
• Density: 1.23±0.1 g/cm3(Predicted)
• PKA: 3.67±0.20(Predicted)
• CAS DataBase Reference: 1-METHOXYCYCLOPROPANE-1-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHOXYCYCLOPROPANE-1-CARBOXYLIC ACID(100683-08-7)
• EPA Substance Registry System: 1-METHOXYCYCLOPROPANE-1-CARBOXYLIC ACID(100683-08-7)

Safety Data

• Hazardous Substances Data: 100683-08-7(Hazardous Substances Data)

Usage

Carboxylic acid derivative

A compound that has a carboxyl functional group (-COOH) attached to a hydrocarbon chain or ring.

Cyclopropane ring

A three-membered cyclic ring structure consisting of three carbon atoms with bond angles of 60 degrees, making it a strained and highly reactive ring system.

Methoxy group

An oxygen atom bonded to a methyl group (-OCH3), which is a functional group that can influence the reactivity and properties of the compound.

Precursor in synthesis

The compound serves as a starting material or building block in the synthesis of various pharmaceuticals and agrochemicals due to its unique structural features.

Potential role as a building block

1-Methoxycyclopropane-1-carboxylic acid has been studied for its possible use in the development of new organic materials and substances with specialized properties.

Biological activities and pharmacological effects

The compound has been investigated for its potential therapeutic effects in the treatment of certain medical conditions, although specific applications are not mentioned in the provided material.

Upstream product

• 29526-97-4 1-methoxy-1-phenylcyclopropane 
• 2790-74-1 1-methoxycyclopropanecarboxylic acid methyl ester 

Relevant articles and documents

ION CHANNEL MODULATORS

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.